Literature DB >> 14695462

Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation.

Takashi Nozawa1, Hiroshi Inoue, Atsushi Iwasa, Ken Okumura, Lee Jong-dae, Akihiko Shimizu, Motonobu Hayano, Katsusuke Yano.   

Abstract

BACKGROUND: Elevation of hemostatic markers may account for the increased risk of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to determine the effects of anticoagulation intensity on hemostatic markers in patients with NVAF. METHODS AND
RESULTS: In 509 patients with NVAF, comprising 263 patients treated with warfarin and 246 patients without warfarin, the hemostatic markers of prothrombin fragment F1.2 (F1.2), fibrin D-dimer, platelet factor 4 (PF4), and beta-thromboglobulin were determined and compared with those in 111 patients with sinus rhythm. F1.2 was inversely related with anticoagulation intensity and D-dimer increased with age. All hemostatic markers, except F1.2, were greater in patients with NVAF than in patients with sinus rhythm. F1.2 and D-dimer were significantly lower in patients with international normalized ratio (INR) > or =1.5 than in NVAF patients without warfarin and were not different between NVAF patients with INR of 1.5-1.9 and with INR > or =2.0.
CONCLUSIONS: Low intensity of anticoagulation (INR 1.5-1.9) suppresses the elevated concentration of F1.2 and D-dimer in patients with NVAF, and might be favorable in Japanese patients with NVAF in view of the balance between prevention of thromboembolism and the adverse effect by warfarin (ie, bleeding).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695462     DOI: 10.1253/circj.68.29

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  10 in total

Review 1.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 2.  Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect.

Authors:  Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

3.  INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation.

Authors:  Jee Eun Chung; Yoo Ri Choi; Jong Mi Seong; Hyen O La; Hye Sun Gwak
Journal:  Int J Clin Pharm       Date:  2015-06-12

4.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

5.  EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  J Arrhythm       Date:  2016-07-11

6.  Effect of sinus rhythm restoration on markers of thrombin generation in atrial fibrillation.

Authors:  Anja Wiedswang Horjen; Ingebjørg Seljeflot; Trygve Berge; Pål Smith; Harald Arnesen; Arnljot Tveit
Journal:  Thromb J       Date:  2017-12-28

7.  The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: A retrospective study.

Authors:  Li-Rui You; Mei Tang
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

8.  Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.

Authors:  Venkatakrishnan Ramakumar; Alexander P Benz; Ganesan Karthikeyan
Journal:  Indian Heart J       Date:  2021-02-10

9.  Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).

Authors:  Stuart J Connolly; John Eikelboom; Paul Dorian; Stefan H Hohnloser; Daniel D Gretler; Uma Sinha; Michael D Ezekowitz
Journal:  Eur Heart J       Date:  2013-03-13       Impact factor: 29.983

10.  Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.

Authors:  Christina Christersson; Lars Wallentin; Ulrika Andersson; John H Alexander; Marco Alings; Raffaele De Caterina; Bernard J Gersh; Christopher B Granger; Sigrun Halvorsen; Michael Hanna; Kurt Huber; Elaine M Hylek; Renato D Lopes; Byung-Hee Oh; Agneta Siegbahn
Journal:  Heart       Date:  2018-09-12       Impact factor: 5.994

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.